Health care and industry overview and challenges

Drug and Biological Development: From Molecule to Product and Beyond

Volumn , Issue , 2007, Pages 5-32

  Evens, Ronald P ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900135835     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-69094-0_1     Document Type: Chapter

References (59)

1. Cowan C, Catlin A., Smith C, Sensenig A. National Health Expenditures, 2002. Health Care Financing Review 2004;25(Summer, # 4):143-66
2. Anonymous. Program Information on Medicare, Medicaid, SCHIP, and other Programs. Centers for Medicare & Medicaid Services. Department of Health and Human Services. June 2002, 1-18
3. Anonymous. Health, United States, 2004. National Center for Health Statistics, Centers for Disease Control and Prevention, U. S. Department of Health and Human Services. 2004
4. Vander Walde L, Choi K, Higgins J. Health Care Industry Market Update. Pharmaceuticals. Centers for Medicare and Medicaid Services. Department of Health and Human Services. January 2003, 1-52
5. Anonymous. Health Care in America. Trends in Utilization. Centers for Disease Control. Department of Health Human Services. 2002, 1-90
6. Lethbridge-Cejka M, Schiller JS, Bernard IL. Summary of Health Statistics for U. S. Adults; National Health Interview Survey for 2002. USDHHS, Centers for Disease Control and Prevention, National Center Health Statistics, July 2004
7. Anonymous. Surveillance for morbidity and mortality among older adults-U. S. (1995-96). MMWR 1999;48(S508):7-25
8. Anonymous. Chronic Disease Overview. Centers for Disease Control. National Center for Chronic Disease Prevention and Health Promotion. US DHHS. 2004, 1-6
9. Anonymous. The Value of Investment in Health Care. Pharmaceutical Research and Manufacturers Association. 2002, 1-8
10. Tufts CSDD. Outlook 2005;1-8
11. Tufts CSDD. Outlook 2004;1-8
12. Tufts CSDD. Outlook 2003;1-5
13. Tufts CSDD. Outlook 2002;1-5
14. Tufts CSDD. Outlook 2001;1-5
15. Anonymous. Profile pharmaceutical industry 2004, Focus on innovation. PhRMA, 2004
16. Anonymous. PhRMA. Industry profile 2003. Prescription medicines 25 years ago and today: changing trends, enduring needs. 1-81
17. Gray N. Our 6th annual report of the world's top 50 pharma companies. Pharmaceutical Executive 2005;25(5):83-94
18. Humphreys A. Mayer R. 11th annual report, World's best-selling medicines. Med Ad News 2005;24(5):1, 24-40
19. 15th annual report top 50 pharmaceutical companies. Med Ad News 2003;22(9):4-19
20. Ernst & Young. The economic contributions of the biotechnology industry to the US economy. May, 2000, Biotechnology Industry Organization
21. Ernst & Young. Resurgence: The Americas perspective. 2004
22. Lamberti MJ (Ed). State of the Clinical Trials Industry, 5th Ed. Thomson, CenterWatch. 2005
23. Lahteenmaki R, Lawrence S. Public biotechnology 2004-the numbers. Nature Biotechnology 2005;23(6):663-7
24. Tufts CSDD. Backgrounder: a methodology for counting costs for pharmaceutical R&D. Recent News. November 1, 2001
25. Tufts CSDD. Total cost to develop a new prescription drug, including cost of post-approval research, is $897 million. Recent News. May 13, 2003
26. Dickson M, Gagnon J P. Key factors in the rising cost of new drug discovery and development. Nature Reviews Drug Discovery 2004;3(5):417-29
27. PhRMA. 2004 Survey. New medicines in development. Biotechnology. Pharmaceutical Research and Manufacturers Association, Washington, DC, 2005, 1-44
28. From pipeline to market 2004. Areas of interest. R&D Directions 2004;10(6):8-18
29. King J. Advances in medicine. 100 great investigational drugs. R&D Directions 2004;10(3):31-51
30. Ernst & Young. Progressions. Global Pharmaceutical Report. 2004 32
31. Garaud J-J The Most Diversified Development Pipeline, Innovation, Focus, Productivity. R&D Directions 2004 Drug Development Summit, How to Build and Maintain a Winning Pipeline. Feb. 8-11, 2004
32. Anonymous. Report to the nation 2003. Improving public health through human drugs. Center for Drug Evaluation and Research. Food and Drug Administration. U. S. Department of Health and Human Services
33. Tufts CSDD. Postmarketing studies becoming essential to new drug development in the U. S. CSDD. Recent News. July 6, 2004
34. Getz KA, De Bruin A. Speed demons of drug development. Pharmaceutical Executive 2000;20(7):78-84
35. Goldberg M, Davenport B, Mortellito T. The big squeeze. Sales forces are still growing, says a new survey. Pharmaceutical Executive 2004;24(1):40-6
36. Guy P. Rising to the productivity challenge. A strategic framework for bipharma. Boston Consulting Group. July 2004
37. Lawyer P, Kirstein A, Yabuki H, Gjaja M, Kush D. High science: a best-practice formula for driving innovation. In Vivo The Business & Medicine Report 2004;22(4):1-12
38. Engel S, King J. Biotech innovation. Pipeline gaps. Can biotech fill them? R&D Directions 2004;10(7):42-56
39. Booth B, Zemmell R. Prospects for productivity. Nature Reviews Drug Discovery 2004;3(5):451-6
40. The pipeline problem. The pipeline solution. R&D Directions 2004;10(5):42-54
41. Rawlins MD. Cutting the cost of drug development. Nature Reviews Drug Discovery 2004;3(4):360-4
42. Cohen CM. A path for improved pharmaceutical productivity. Nature Reviews Drug Discovery 2003;2(9):751-3
43. R&D business. Mostly growth for big pharma in 2003. R&D Directions 2004;10(3):14-15
44. Preziosi P. Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario? Nature Reviews Drug Discovery 2004;3(6):521-6
45. Balekdjian D, Russo M. Managed care update: show us the value. Pharmaceutical Executive special report. September, 2003
46. Tollman P, Guy P, Altshuler J, Flanagan A, Steiner M. A revolution in R&D. How genomics and genetics are transforming the biopharmaceutical industry. Boston Consulting Group, November, 2001
47. R&D Directions 2004 Drug Development Summit, How to Build and Maintain a Winning Pipeline. Feb. 8-11, 2004
48. Edwards MG, Murray F, Yu R. Value creation and sharing among universities, biotechnology and pharma. Nature Biotechnology 2003;21(6):618-24
49. Alzheimers Association, accessed June 2004 at www.alz.org
50. Arthritis Foundation, accessed June 2004 at www.arthritis.org
51. National Cancer Institute, accessed June 2004 at www.nci.nih.gov
52. American Heart Association, accessed June 2005 at www.americanheart.org
53. National Institutes of Mental Health, accessed June 2005 at www.nimh.nih.gov
54. American Diabetes Association, accessed June 2005 at www.diabetes.org
55. National Headache Foundation, accessed Junes 2005 at www.headache.org
56. National Osteoporosis Foundation, accessed June 2005 at www.nof.org
57. Engel S, King J. From Pipeline to market 2004. R&D Directions Suppl. 2004;10(6):35-74
58. Personal Communications & Experiences, Amgen 1989-2002
59. R&D Directions, Summit on Product Development, February 2004